Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma
Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma
Case Scenario: A 52-year old male with mRCC
February 2018
- A 52-year old Caucasian man presented to his physician complaining of severe left-sided back pain
- Laboratory findings: mild anemia, otherwise WNL
- CT scan of the abdomen and pelvis showed a large left renal mass, several small lytic lesions in the lumbar and thoracic vertebrae, and a small pulmonary nodule
- The patient underwent cytoreductive nephrectomy
- Diagnosis; stage IV clear-cell renal cell carcinoma; good-risk
- He received radiation therapy to his spinal lesions and was then started on cabozantinib 60 mg daily
- The patient reported moderate nausea and vomiting and diarrhea after 6 weeks on therapy; he continues to do well with improved tolerance after dose adjustment to 40 mg
- Imaging at 3 months showed a significant decrease in size of the pulmonary nodule
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Unique Challenges of Using IO/TKI Combinations in Metastatic RCC
March 12th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
